PHARMACOGENOMICS
VIRTUAL SUMMIT SERIES

Summit 6: **Moderator**

Dan M. Roden, MD

Dan Roden's research program studies how genetic variation affects human disease susceptibility, with a focus on pharmacogenetics, and on genetic determinants of abnormal heart rhythms, especially those induced by drugs. Under his leadership, Vanderbilt has become internationally recognized for cutting edge programs in Personalized Medicine, including the large (250,000 sample) biobank BioVU and the EHR-based preemptive pharmacogenetic program PREDICT. He has been Principal Investigator for the Vanderbilt sites of the Pharmacogenomics Research Network (2001-2020) and of the Electronic Medical Records and Genomics (eMERGE) Network since 2007 and currently serves as co-PI for the All of Us program's Data and Research Center.

He has received ASCPT's Leon Goldberg Young Investigator Award, Rawls Palmer Progress in Science Award, and Oscar Hunter Award in Therapeutics; the Distinguished Scientist Award from the Heart Rhythm Society and AHA; the inaugural Functional Genomics and Translational Biology Medal of Honor from AHA; the Alumnus Lifetime Achievement Award and the Lucian Award in Cardiovascular Research from McGill; and the Jay and Jeanie Schottenstein prize in cardiovascular sciences from the Ohio State University. He has been elected to membership in the American Society for Clinical Investigation and the Association of American Physicians, and fellowship in the AAAS.

Summit 6: **Panelists**



Peter J. Hulick, MD, MMSc, FACMG

Dr. Hulick is the Medical Director of the Mark R. Neaman Center for Personalized Medicine and Division Head for the Center for Medical Genetics at NorthShore University HealthSystem (NorthShore), which applies genetic analysis to prevention, diagnosis and treatment of inherited diseases and disorders. He joined NorthShore as an attending physician in medical genetics in 2008 and became Division Head of Medical Genetics in 2012.

Dr. Hulick also serves as a Clinical Assistant Professor in the Department of Human Genetics at the University of Chicago Pritzker School of Medicine. He has authored or co-authored more than 40 peer reviewed journal articles.

Dr. Hulick earned his medical degree from Jefferson Medical College in 2001. He completed a residency in internal medicine at St. Luke's Hospital – Mayo Clinic, and completed a clinical fellowship in medical genetics at Harvard Medical School. He also earned a master's degree in medical science from Harvard Medical School in 2007.

Josh F. Peterson, MD, MPH, FACMI

Josh Peterson, MD, MPH, is a Professor of Biomedical Informatics and Medicine in the School of Medicine at Vanderbilt University Medical Center. Dr. Peterson received his MD through the Vanderbilt University School of Medicine in 1997 and completed an Internal Medicine residency at Duke University Medical Center, a fellowship in General Internal Medicine at the Brigham and Women's Hospital, and a Master of Public Health degree at the Harvard School of Public Health. Dr. Peterson's research interests are in precision medicine with a focus on systems of care to improve drug safety and efficacy, and the translation of genomic technologies to practice. He serves as a Principal Investigator within the IGNITE, eMERGE and RISE genomic medicine consortia. Dr. Peterson is also the Director for the VUMC Center for Precision Medicine and serves as Program Director for the Vanderbilt Genomic Medicine training program.

Alicia Zhou, PhD

Dr. Zhou is the Chief Science Officer at Color. She is responsible for leading research collaborations with academic institutions, biopharmaceutical companies, and large population initiatives. She and her team initiates, executes, and publishes collaborations for peer-reviewed publication initiated by Color's scientists and engineers. In addition, Dr. Zhou is an active part of Color's market development team for population genomics, SARS-CoV-2 testing, COVID-19 vaccine distribution and population research. Dr. Zhou received her Ph.D. at Harvard and performed her postdoctoral work at UCSF with an emphasis on cancer genetics. Dr. Zhou is also the co-PI for the NIH's "All of Us Research Program" Genetic Counseling Resource Award.

George E. MacKinnon III, PhD, MS, RPh, FASHP, FNAP

Dr. MacKinnon began responsibilities as Founding Dean of the School of Pharmacy at the Medical College of Wisconsin (MCW) in 2015. He received his BS (Pharmacy) and MS (Hospital Pharmacy) from the University of Wisconsin-Madison School of Pharmacy, completing two-years of post-graduate pharmacy residency training at University of Wisconsin Hospital and Clinics. He earned his PhD in Educational Leadership and Policy Studies from Loyola University Chicago. He is a Fellow of the American Society of Health-System Pharmacists (FASHP)and Distinguished Scholar Fellow of the National Academies of Practice (NAP). His previous appointments include Founding Dean of Pharmacy & Vice Provost for Health Sciences at Roosevelt University Chicago, Vice President of Academic Affairs with the American Association of Colleges of Pharmacy,

and Director of Global Health Economics & Outcomes Research of Abbott Laboratories. Dr. MacKinnon is Editor of, *Understanding Health Outcomes and Pharmacoeconomics*. He serves on the editorial boards of the journals Pharmacy, the *Wisconsin Medical Journal*, and *Pharmacy Times*. His research interests align in expanding pharmacist care models (e.g., primary care, pharmacogenomics, immunizations) in collaborative approaches to team-based care and principles of team-science. Most recently he developed a course on Pharmacogenomics in the MS Precision Medicine program at MCW.

Trish Brown, MS, CGC

Trish Brown is a board certified, genetic counselor with over two decades of experience in clinical genetics. She is currently the Director, AMR Payer Partner & Field Market Access Lead at Illumina. Ms. Brown is experienced in commercialization of genomic tests, operations, and lab benefit management. Prior to joining Illumina, she has held executive leadership roles at distinguished corporations such as LabCorp and Medco, and the entrepreneurial successes DNA Direct, Fabric Genomics and BeaconLBS.

Jill Hagenkord, MD, FCAP

Dr. Hagenkord is the Chief Medical Officer of Optum Genomics. Jill is a board-certified pathologist with subspecialty boards in molecular genetic pathology and an additional fellowship in pathology/oncology informatics. Jill's expertise is in health product strategy, coding/coverage/reimbursement of molecular diagnostics, medical and regulatory affairs, health policy, clinical laboratory medicine, molecular diagnostics, population health, provider education, patient engagement, and medical diligence.

Dr. Hagenkord serves on a number of medical professional societies as an active member in the Association for Molecular Pathology, the College of American Pathologists, American College of Medical Genetics and Genomics, and the National Academies of Science, Engineering, and Medicine's Roundtable on Genomics and Precision Health. Jill received her MD from Stanford University School of Medicine in 1999, did residency training at the University of California at San Francisco and the University of Iowa, and completed fellowships at the University of Pittsburgh Medical Center. Subsequently, Dr. Hagenkord practiced pathology at Creighton University Medical Center where she founded iKaryos Diagnostics. Jill was previously the Chief Medical Officer at Color Genomics, 23andMe, Invitae, and Complete Genomics. More details on Jill's experience can be found here

William E. Evans, PharmD

Dr. Evans joined the St. Jude Children's Research Hospital (SJCRH) faculty in 1976, chaired the Pharmaceutical Sciences Department (1986-2002), served as Scientific Director & EVP (2002-2004), and as President and CEO (2004-2014). He currently holds the St. Jude Endowed Chair of Pharmacogenomics and is a Professor at the University of Tennessee Colleges of Medicine and Pharmacy.

Evans received his BSc and PharmD degrees from the University of Tennessee HSC (1973, 1974) and spent a sabbatical year (1987-88) at the University of Basel (with Prof. Urs Meyer). He has received honorary doctoral degrees from Rhodes College, the Ohio State University and the University of Florida.

For the past 40 years his research has focused on the pharmacodynamics and pharmacogenomics of anticancer agents in children, for which he has received three consecutive NIH MERIT Awards from NCI. Evans has authored over 400 scientific publications and has received several national awards for his research, including the 2009 Pediatric Oncology Award from ASCO (with Mary V. Relling), the 2009 Team Science Prize from AACR (shared), the 2012 Remington Medal from APhA, the 2013 Oscar B. Hunter Award from ASCPT and the 2018 Parker Medal from ACCP.

He was elected to the Institute of Medicine of the US National Academy of Sciences in 2002 (now the US National Academy of Medicine) and to the German National Academy of Sciences in 2016.